Teacher Insights: How Digital Technology Helps in Growth and Access to Quality Education  |  Management lessons: How Brands Use CARE to Stay on Top in Instagram  |  Hobbies &Trends: At Full Throttle  |  Finance: Bitcoin Mobile Apps Vulnerable to Security Threats: Guan-Hua Tu, MSU  |  International Edu News: Use plants' ability to tell the time to make food production more sustainable  |  International Edu News: Scientists develop new class of cancer drug with potential to treat leukaemia  |  International Edu News: Loan applications processed around midday more likely to be rejected  |  International Edu News: Researchers find climate change impacts plankton – a key marine food source  |  International Edu News: Nature must be a partner, not just a provider of services – Oxford report  |  National Edu News: Approval to MoU between India and UK on Global Innovation Partnership  |  National Edu News: Transfer of CSIR-CMERI technologies to three MSMEs  |  Parent Interventions: Child Learning Programs: How to Find the Right One for You  |  Rajagiri Round Table: Fitness Challenge for the Nation  |  Education Information: West Bengal Scholarship 2021  |  Education Information: What is PMEGP Scheme? How can you get it?  |  
April 13, 2021 Tuesday 01:18:05 PM IST

HGCO19: starting the enrolment for the PhaseI/II human clinical trials

The Department of Biotechnology (DBT), Ministry of Science & Technologyhas announced that it has approved additional funding towards clinical studies of India's'first of its kind' mRNA-based COVID-19 vaccine - HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd.

This funding has been awarded under the'Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission'by DBT's dedicated Mission Implementation Unit at BiotechnologyIndustry Research Assistance Council (BIRAC) after multiplerounds of evaluation of all the applications that were submitted in response to the 'Request for Expression of Interest (REOI)'under Mission COVID Surakshafor the'Development of COVID-19 vaccine candidate(s)'.

DBT has been hand-holding Gennova's right from the start and has facilitated establishing Gennova's mRNA-based next-generation vaccine manufacturing platform by providing seed funding for the development of HGCO19. Gennova, in collaboration with HDT Biotech Corporation, USA,has developed theCOVID-19mRNA vaccine – HGCO19.

HGCO19 has already demonstrated safety, immunogenicity, neutralization antibody activityin the rodent and non-human primate models. The neutralizing antibody response of the vaccine in mice and non-human primates was comparable with the sera from the convalescent patients of COVID-19.Gennova has completed two preclinical toxicity studies as per theDrugs and Cosmetics (Ninth Amendment) Rules - 2019,to establish the safety of the vaccine candidate and got regulatory clearance from the Review Committee on Genetic Manipulation (RCGM) and office of the Drugs Controller General of India (DCGI), Central Drugs Standard Control Organization (CDSCO), Government of India, to conduct clinical trials. Gennova has initiated the process to enroll healthy volunteers from the Phase I/II clinical trials.


mRNA vaccines are considered safe as mRNA is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms. They are highly efficacious because of their inherent capability of being translatable into the protein structure inside the cell cytoplasm. Additionally, mRNA vaccines are fully synthetic and do not require a host for growth, e.g., eggs or bacteria. Therefore, they can be quickly manufactured inexpensively under cGMP conditions to ensure their "availability" and "accessibility" for mass vaccination on a sustainable basis.

The establishment of such atechnology platform will empower India to handle the COVID-19 pandemic and ensure the preparedness for any future pandemic or endemic stage that will follow (mutation in the virus, unvaccinated low-risk population, newborns,etc.)by utilizing its rapid development path. Speed of this platform technology has been already proven during the COVID-19 outbreak as mRNA candidate was the first to enter the human trails globally

Comments